/BIOVIC-B.ST
BIOVIC-B.ST Stock - Biovica International AB (publ)
Healthcare|BiotechnologySTO
$0.34+0.30%
+$0.00 (+0.30%) • Dec 23
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.62
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.37
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BIOVIC-B.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.33 – $0.34
TARGET (TP)$0.39
STOP LOSS$0.31
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.44
52W High$2.35
52W Low$0.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.62M | $7.29M | $3.38M | $2.04M | $2.08M |
| Gross Profit | $8.08M | $6.88M | $4.62M | $4.67M | $5.27M |
| Gross Margin | 93.8% | 94.3% | 136.4% | 228.2% | 253.7% |
| Operating Income | $-85,839,000 | $-126,845,000 | $-110,457,000 | $-60,101,000 | $-40,181,000 |
| Net Income | $-87,624,000 | $-124,823,000 | $-110,492,000 | $-60,003,000 | $-39,483,000 |
| Net Margin | -1016.6% | -1712.2% | -3265.1% | -2934.1% | -1901.0% |
| EPS | $-0.95 | $-2.14 | $-2.98 | $-1.96 | $-1.29 |
Company Overview
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BIOVIC-B.STBeat Rate
27%
Last 15 quarters
Avg Surprise
-39.3%
EPS vs Estimate
Beats / Misses
4/11
Last 12 quarters
Latest EPS
$-0.05
Q4 2025
EPS Surprise History
Q1 24
-15.8%
$-0.44vs$-0.38
Q2 24
-20.5%
$-0.47vs$-0.39
Q3 24
-22.7%
$-0.27vs$-0.22
Q4 24
+4.2%
$-0.23vs$-0.24
Q1 25
+17.9%
$-0.23vs$-0.28
Q2 25
+32.3%
$-0.21vs$-0.31
Q3 25
-24.8%
$-0.11vs$-0.09
Q4 25
+36.4%
$-0.05vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Jun 17, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Dec 18, 2025 | $-0.08 | $-0.05 | +36.4% | ✓ BEAT |
Q3 2025 | Sep 11, 2025 | $-0.09 | $-0.11 | -24.8% | ✗ MISS |
Q2 2025 | Jun 19, 2025 | $-0.31 | $-0.21 | +32.3% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q4 2024 | Dec 12, 2024 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q3 2024 | Sep 12, 2024 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q2 2024 | Jun 18, 2024 | $-0.39 | $-0.47 | -20.5% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.38 | $-0.44 | -15.8% | ✗ MISS |
Q4 2023 | Nov 28, 2023 | $-0.28 | $-0.53 | -89.3% | ✗ MISS |
Q3 2023 | Sep 6, 2023 | $-0.30 | $-0.70 | -133.3% | ✗ MISS |
Q2 2023 | Jun 21, 2023 | $-0.45 | $-0.81 | -80.0% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.60 | $-0.64 | -6.7% | ✗ MISS |
Q4 2022 | Dec 15, 2022 | — | $-0.81 | — | — |
Q3 2022 | Aug 31, 2022 | — | $-0.73 | — | — |
Q2 2022 | Jun 30, 2022 | $-0.37 | $-0.62 | -68.9% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.29 | $-0.49 | -68.7% | ✗ MISS |
Q4 2021 | Dec 1, 2021 | $-0.20 | $-0.50 | -150.0% | ✗ MISS |
Q3 2021 | Aug 31, 2021 | — | $-0.42 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BIOVIC-B.ST
What is BIOVIC-B.ST's current stock price?
Biovica International AB (publ) (BIOVIC-B.ST) is currently trading at $0.34 per share. The stock has moved +0.30% today.
What is the analyst price target for BIOVIC-B.ST?
No analyst price targets are currently available for this stock.
What sector is Biovica International AB (publ) in?
Biovica International AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is BIOVIC-B.ST's market cap?
Biovica International AB (publ) has a market capitalization of $0.07 billion, making it a small-cap company.
Does BIOVIC-B.ST pay dividends?
No, Biovica International AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
ATORX.ST
Alligator Bioscience AB (publ)
$0.34
Mkt Cap: $0.0B
BIOSGN.ST
Biosergen AB
$42.60
Mkt Cap: $0.1B
ICO.ST
Iconovo AB (publ)
$1.14
Mkt Cap: $0.1B
IMMNOV.ST
Immunovia AB (publ)
$0.23
Mkt Cap: $0.1B
NICA.ST
Nanologica AB (publ)
$0.71
Mkt Cap: $0.1B
NXTCL.ST
NextCell Pharma AB
$0.70
Mkt Cap: $0.1B
PILA.ST
Pila Pharma AB (publ)
$2.20
Mkt Cap: $0.1B
SPRINT.ST
Sprint Bioscience AB (publ)
$1.45
Mkt Cap: $0.2B
XBRANE.ST
Xbrane Biopharma AB (publ)
$10.88
Mkt Cap: $0.1B
Explore stocks similar to BIOVIC-B.ST for comparison